Ellevest, Inc. Madrigal Pharmaceuticals, Inc. Transaction History

Ellevest, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$231.06 - $307.08 $1,617 - $2,149	7 New	7 $1,000
Q2 2022 Jul 18, 2022	SELL	$58.04 - $100.2 $2,669 - $4,609	-46 Closed	0 $0
Q4 2021 Jan 24, 2022	BUY	$72.34 - $95.09 $1,808 - $2,377	25 Added 119.05%	46 $4,000
Q3 2021 Oct 19, 2021	SELL	$78.35 - $105.02 $940 - $1,260	-12 Reduced 36.36%	21 $2,000
Q2 2021 Jul 13, 2021	BUY	$97.2 - $137.59 $194 - $275	2 Added 6.45%	33 $3,000
Q4 2020 Feb 04, 2021	BUY	$110.06 - $133.7 $1,100 - $1,337	10 Added 47.62%	31 $3,000
Q1 2020 Apr 13, 2020	BUY	$66.76 - $93.49 $1,401 - $1,963	21 New	21 $1,000

334

22.3M

960K

940K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.81B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

Stay updated on Ellevest, Inc. with notifications on news.